{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:24:34Z","timestamp":1787027074423,"version":"build-2736575974"},"reference-count":246,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"\n Background<\/jats:title>\n The ubiquitin\u2013proteasome pathway is a critical therapeutic target in malignancies, particularly multiple myeloma. The development of proteasome inhibitors (PIs) has marked a milestone in multiple myeloma therapy and now constitutes the backbone of frontline treatment regimens. However, primary and acquired resistance remain a major challenge, underscoring the need to identify new PIs as well as agents that can resensitize resistant cells.<\/jats:p>\n <\/jats:sec>\n \n Method<\/jats:title>\n \n This review provides an overview of the current clinical applications of PIs and offers a comprehensive summary of natural products that either directly target the proteasome or enhance cellular sensitivity to PIs. Relevant clinical trials and literature published up to 2025 were retrieved from PubMed, Web of Science, Google Scholar, and\n ClinicalTrials.gov<\/jats:ext-link>\n , focusing on the biological and pharmacological activities, structure-activity relationships, and clinical outcomes.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n In this review, we summarize the current clinical applications of PIs and specifically highlight the discovery of natural products that directly target the proteasome or enhance cellular sensitivity to PIs. We also discuss the clinical progress of marizomib, the only natural product-derived PI, that has advanced to clinical trials. Despite existing challenges, natural product-derived PIs hold significant potential for the development of next-generation therapies that can overcome resistance and improve clinical outcomes.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n The development of novel natural product-derived PIs and rational combination strategies offers promising opportunities for overcoming resistance in cancer therapy. Although challenges remain, the remarkable structural diversity of natural products provides a rich reservoir for drug discovery, underscoring the importance of continued exploration and innovation in this field.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fphar.2026.1806787","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:31:49Z","timestamp":1777872709000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting the proteasome in cancer therapy: development and future opportunities in natural products"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiu","family":"Zhao","sequence":"first","affiliation":[{"name":"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, West China School of Pharmacy, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Liu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, West China School of Pharmacy, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrui","family":"Zeng","sequence":"additional","affiliation":[{"name":"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, West China School of Pharmacy, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liao","sequence":"additional","affiliation":[{"name":"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, West China School of Pharmacy, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, West China School of Pharmacy, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Translational Research in Hematological Malignancies, Houston Methodist Neal Cancer Center, Houston Methodist Academic Institute","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, West China School of Pharmacy, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifeng","family":"Chen","sequence":"additional","affiliation":[{"name":"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, West China School of Pharmacy, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Xian","sequence":"additional","affiliation":[{"name":"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, West China School of Pharmacy, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Qin","sequence":"additional","affiliation":[{"name":"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, West China School of Pharmacy, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1186\/s12906-016-1358-8","article-title":"Methylferulate from Tamarix aucheriana inhibits growth and enhances chemosensitivity of human colorectal cancer cells: possible mechanism of action","volume":"16","author":"Abaza","year":"2016","journal-title":"BMC Complement. Altern. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.vetpar.2009.09.049","article-title":"Evaluation of the in vitro growth-inhibitory effect of epoxomicin on B abesia parasites","volume":"167","author":"Aboulaila","year":"2010","journal-title":"Vet. Parasitol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.tiv.2017.12.001","article-title":"Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-\u03baB pathways","volume":"47","author":"Allegra","year":"2018","journal-title":"Toxicol. Vitro"},{"key":"B4","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3390\/ph17070815","article-title":"Descriptive analysis of adverse events reported for new multiple myeloma medications using FDA Adverse Event Reporting System (FAERS) databases from 2015 to 2022","volume":"17","author":"Alrasheed","year":"2024","journal-title":"Pharmaceuticals"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4830","DOI":"10.1158\/1078-0432.Ccr-11-3007","article-title":"A phase I single-agent Study of twice-weekly consecutive-day dosing of the proteasome inhibitor Carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma","volume":"18","author":"Alsina","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"961012","DOI":"10.3389\/fphar.2022.961012","article-title":"Exploring the mechanisms of neurotoxicity caused by fuzi using network pharmacology and molecular docking","volume":"13","author":"An","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1434812","DOI":"10.3389\/fphar.2024.1434812","article-title":"Blestriarene C exerts an inhibitory effect on triple-negative breast cancer through multiple signaling pathways","volume":"15","author":"An","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.tips.2025.10.015","article-title":"Sodium's role and therapeutic targeting in cancer","volume":"47","author":"An","year":"2026","journal-title":"Trends Pharmacol. Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.jpha.2023.06.004","article-title":"Ginsenoside Rg5 enhances the radiosensitivity of lung adenocarcinoma via reducing HSP90-CDC37 interaction and promoting client protein degradation","volume":"13","author":"Bai","year":"2023","journal-title":"J. Pharm. Anal."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1021\/jm0701324","article-title":"Linear TMC-95-Based proteasome inhibitors","volume":"50","author":"Basse","year":"2007","journal-title":"J. Med. Chem."},{"key":"B11","doi-asserted-by":"publisher","first-page":"5388","DOI":"10.1182\/blood.V130.Suppl_1.5388.5388","article-title":"Defining the Most effective proteasome inhibition in multiple myeloma: Head-to-Head comparison of currently available proteasome inhibitors","volume":"130","author":"Besse","year":"2017","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"108733","DOI":"10.1016\/j.cbi.2019.108733","article-title":"Plumbagin induces paraptosis in cancer cells by disrupting the sulfhydryl homeostasis and proteasomal function","volume":"310","author":"Binoy","year":"2019","journal-title":"Chem.-Biol. Interact."},{"key":"B13","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.bbrc.2018.01.100","article-title":"Piperlongumine and some of its analogs inhibit selectively the human immunoproteasome over the constitutive proteasome","volume":"496","author":"Bosc","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B14","doi-asserted-by":"publisher","first-page":"154617","DOI":"10.1016\/j.phymed.2022.154617","article-title":"Identification of the target protein and molecular mechanism of honokiol in anti-inflammatory action","volume":"109","author":"Cai","year":"2023","journal-title":"Phytomedicine"},{"key":"B15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","article-title":"NCCN guidelines\u00ae insights: multiple myeloma, version 3.2022: featured updates to the NCCN guidelines","volume":"20","author":"Callander","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"B16","doi-asserted-by":"publisher","first-page":"177964","DOI":"10.1016\/j.ejphar.2025.177964","article-title":"Cuproptosis induced by curcumin interfering with proliferation and energy metabolism in colorectal cancer: 3D tumor model and computational simulations reveal curcumin inhibition of HSPD1 and CALCOCO2","volume":"1003","author":"Cao","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/bjc.2017.302","article-title":"A phase I\/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed\/refractory multiple myeloma","volume":"117","author":"Cavenagh","year":"2017","journal-title":"Br. J. Cancer."},{"key":"B18","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/eji.1830270148","article-title":"The proteasome-specific inhibitor lactacystin blocks presentation of cytotoxic T lymphocyte epitopes in human and murine cells","volume":"27","author":"Cerundolo","year":"1997","journal-title":"Eur. J. Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jep.2015.05.006","article-title":"Molecular mechanisms of Polyphyllin I-induced apoptosis and reversal of the epithelial-mesenchymal transition in human osteosarcoma cells","volume":"170","author":"Chang","year":"2015","journal-title":"J. Ethnopharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1182\/blood-2009-03-213009","article-title":"Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma","volume":"115","author":"Chauhan","year":"2010","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"R80","DOI":"10.1186\/bcr1797","article-title":"Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts","volume":"9","author":"Chen","year":"2007","journal-title":"Breast Cancer Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1038\/s41401-025-01612-9","article-title":"Isoginkgetin, a natural biflavonoid from Ginkgo biloba, inhibits inflammatory response in endothelial cells via suppressing NF-\u03baB activation","volume":"46","author":"Chen","year":"2025","journal-title":"Acta Pharmacol. Sin."},{"key":"B23","doi-asserted-by":"publisher","first-page":"113770","DOI":"10.1016\/j.jep.2020.113770","article-title":"Remodeling the homeostasis of pro- and anti-angiogenic factors by Shenmai injection to normalize tumor vasculature for enhanced cancer chemotherapy","volume":"270","author":"Cheng","year":"2021","journal-title":"J. Ethnopharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4836","DOI":"10.1002\/anie.201402428","article-title":"Total synthesis of Syringolin A and improvement of its biological activity","volume":"53","author":"Chiba","year":"2014","journal-title":"Angew. Chem.-Int. Ed."},{"key":"B25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejphar.2011.01.039","article-title":"Identification of angular naphthopyrones from the Philippine echinoderm Comanthus species as inhibitors of the NF-\u03baB signaling pathway","volume":"657","author":"Chovolou","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.3390\/ijms23031206","article-title":"Oleacein Attenuates lipopolysaccharide-induced inflammation in THP-1-Derived macrophages by the inhibition of TLR4\/MyD88\/NF-\u03baB pathway","volume":"23","author":"Cirmi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1002\/cbic.200900411","article-title":"Syringolin A selectively labels the 20 S proteasome in Murine EL4 and wild-type and Bortezomib-Adapted leukaemic cell lines","volume":"10","author":"Clerc","year":"","journal-title":"ChemBioChem"},{"key":"B28","doi-asserted-by":"publisher","first-page":"6507","DOI":"10.1073\/pnas.0901982106","article-title":"Synthetic and structural studies on syringolin A and B reveal critical determinants of selectivity and potency of proteasome inhibition","volume":"106","author":"Clerc","year":"","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B29","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1039\/C0CC02238A","article-title":"The natural product hybrid of Syringolin A and Glidobactin A synergizes proteasome inhibition potency with subsite selectivity","volume":"47","author":"Clerc","year":"2011","journal-title":"Chem. Commun."},{"key":"B30","unstructured":"Phase 2 clinical trial of NPI-0052 in patients with relapsed or relapsed\/refractory multiple myeloma\n \n \n 2007"},{"key":"B31","article-title":"NPI-0052 and vorinostat in patients with non-small cell lung cancer","volume-title":"Pancreatic cancer, Melanoma or lymphoma","year":"2008"},{"key":"B32","unstructured":"Stage 1: marizomib + bevacizumab in WHO Gr IV GBM; stage 2: marizomib alone; stage 3: combination of marizomib and bevacizumab\n \n \n 2015"},{"key":"B33","unstructured":"A phase III trial of with marizomib in patients with newly diagnosed glioblastoma (MIRAGE)\n \n \n 2018"},{"key":"B34","volume-title":"Marizomib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord Ependymoma","year":""},{"key":"B35","unstructured":"Phase I Study of Marizomib + Panobinostat for children with DIPG (DIPG)"},{"key":"B36","unstructured":"Marizomib Central Nervous System (CNS)\n \n \n 2024"},{"key":"B37","doi-asserted-by":"publisher","first-page":"13437","DOI":"10.1074\/jbc.272.20.13437","article-title":"Lactacystin and clasto-Lactacystin \u03b2-Lactone modify multiple proteasome \u03b2-Subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation","volume":"272","author":"Craiu","year":"1997","journal-title":"J. Biol. Chem."},{"key":"B38","doi-asserted-by":"publisher","first-page":"155101","DOI":"10.1016\/j.phymed.2023.155101","article-title":"Natural products for the treatment of neurodegenerative diseases","volume":"121","author":"Cui","year":"2023","journal-title":"Phytomedicine"},{"key":"B39","doi-asserted-by":"publisher","first-page":"4080","DOI":"10.1128\/aac.00088-09","article-title":"The proteasome inhibitor Epoxomicin has potent Plasmodium falciparum gametocytocidal activity","volume":"53","author":"Czesny","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"B40","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jsbmb.2017.03.009","article-title":"Neurotoxicity of the steroidal alkaloids tomatine and tomatidine is RIP1 kinase- and caspase-independent and involves the eIF2\u03b1 branch of the endoplasmic reticulum","volume":"171","author":"Da Silva","year":"2017","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e14153","DOI":"10.1371\/journal.pone.0014153","article-title":"Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB","volume":"5","author":"Dai","year":"2010","journal-title":"PLoS One"},{"key":"B42","doi-asserted-by":"publisher","first-page":"155054","DOI":"10.1016\/j.phymed.2023.155054","article-title":"Celastrol as an intestinal FXR inhibitor triggers tripolide-induced intestinal bleeding: underlying mechanism of gastrointestinal injury induced by Tripterygium wilfordii","volume":"121","author":"Dai","year":"2023","journal-title":"Phytomedicine"},{"key":"B43","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/bjh.13780","article-title":"Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD\u00ae immunomodulatory drug pomalidomide","volume":"171","author":"Das","year":"2015","journal-title":"Br. J. Haematol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/bjc.1998.183","article-title":"The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo-and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-\u03b1-initiated apoptosis","volume":"77","author":"Delic","year":"1998","journal-title":"Br. J. Cancer."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/jcb.25783","article-title":"P-Glycoprotein inhibition sensitizes human breast cancer cells to proteasome inhibitors","volume":"118","author":"Deshmukh","year":"2017","journal-title":"J. Cell. Biochem."},{"key":"B46","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1021\/jm4002007","article-title":"Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome","volume":"56","author":"Desvergne","year":"2013","journal-title":"J. Med. Chem."},{"key":"B47","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1093\/neuonc\/nov299","article-title":"Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier","volume":"18","author":"Di","year":"2016","journal-title":"Neuro-Oncology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1074\/jbc.272.1.182","article-title":"Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells","volume":"272","author":"Dick","year":"1997","journal-title":"J. Biol. Chem."},{"key":"B49","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.2174\/0109298673268932230920063933","article-title":"CAR-T therapy in relapsed refractory multiple myeloma","volume":"31","author":"Ding","year":"2024","journal-title":"Curr. Med. Chem."},{"key":"B50","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3390\/ph16010092","article-title":"Targeting the interplay of autophagy and ROS for cancer therapy: an updated overview on phytochemicals","volume":"16","author":"Dong","year":"2023","journal-title":"Pharmaceuticals"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1448144","DOI":"10.3389\/fphar.2024.1448144","article-title":"Adverse event profile of albumin-bound paclitaxel: a real-world pharmacovigilance analysis","volume":"15","author":"Duan","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1053\/j.seminhematol.2012.04.009","article-title":"An historic perspective of proteasome inhibition","volume":"49","author":"Esseltine","year":"2012","journal-title":"Semin. Hematol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e202401848","DOI":"10.1002\/cbdv.202401848","article-title":"Neolignan Kadsurenin F modulates proteostatic pathways and possesses potent anti-inflammatory properties","volume":"22","author":"Evangelakou","year":"2025","journal-title":"Chem. Biodivers."},{"key":"B54","doi-asserted-by":"publisher","first-page":"10280","DOI":"10.18632\/oncotarget.2163","article-title":"Targeting hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab","volume":"5","author":"Falchook","year":"2014","journal-title":"Oncotarget"},{"key":"B55","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.1200\/jco.2006.06.1853","article-title":"Randomized phase II Study of Bortezomib alone and Bortezomib in combination with docetaxel in previously treated advanced Non\u2013Small-Cell lung cancer","volume":"24","author":"Fanucchi","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/anie.200390115","article-title":"Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new Genus salinospora","volume":"42","author":"Feling","year":"2003","journal-title":"Angew. Chem.-Int. Ed."},{"key":"B57","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1126\/science.7732382","article-title":"Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by Lactacystin","volume":"268","author":"Fenteany","year":"1995","journal-title":"Science"},{"key":"B58","doi-asserted-by":"publisher","first-page":"108595","DOI":"10.1016\/j.pharmthera.2024.108595","article-title":"Olea europaea L-derived secoiridoids: beneficial health effects and potential therapeutic approaches","volume":"254","author":"Filardo","year":"2024","journal-title":"Pharmacol. Ther."},{"key":"B59","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/leu.2015.190","article-title":"Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells","volume":"30","author":"Fink","year":"2016","journal-title":"Leukemia"},{"key":"B60","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/leu.2011.256","article-title":"Impaired bortezomib binding to mutant \u03b25 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells","volume":"26","author":"Franke","year":"2012","journal-title":"Leukemia"},{"key":"B61","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-pharmtox-010919-023603","article-title":"Proteasome inhibitor drugs","volume":"60","author":"Fricker","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"100053","DOI":"10.1016\/j.pharmr.2025.100053","article-title":"Activating autophagy to eliminate toxic protein aggregates with small molecules in neurodegenerative diseases","volume":"77","author":"Fu","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1002\/cbic.201300499","article-title":"Identification of a molecular target of a novel fungal Metabolite, pyrrolizilactone, by phenotypic profiling systems","volume":"14","author":"Futamura","year":"2013","journal-title":"ChemBioChem"},{"key":"B64","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/s0161-5890(98)00053-4","article-title":"The proteasome inhibitor lactacystin prevents the generation of an endoplasmic reticulum leader\u2014derived T cell epitope","volume":"35","author":"Gallimore","year":"1998","journal-title":"Mol. Immunol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2022.12.005","article-title":"Cardiovascular toxicity of proteasome inhibitors: underlying mechanisms and management strategies","volume":"5","author":"Georgios","year":"2023","journal-title":"JACC-Cardiooncol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1021\/np501060k","article-title":"Cystargolides, 20S proteasome inhibitors isolated from Kitasatospora cystarginea","volume":"78","author":"Gill","year":"2015","journal-title":"J. Nat. Prod."},{"key":"B67","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/386463a0","article-title":"Structure of 20S proteasome from yeast at 2.4\u00c5 resolution","volume":"386","author":"Groll","year":"1997","journal-title":"Nature"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1021\/ja993588m","article-title":"Crystal structure of Epoxomicin:20S proteasome reveals a molecular basis for selectivity of \u03b1\u2018,\u03b2\u2018-Epoxyketone proteasome inhibitors","volume":"122","author":"Groll","year":"2000","journal-title":"J. Am. Chem. Soc."},{"key":"B69","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1006\/jmbi.2001.4869","article-title":"Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor11Edited by I. A. Wilson","volume":"311","author":"Groll","year":"2001","journal-title":"J. Mol. Biol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.chembiol.2006.04.005","article-title":"TMC-95-Based inhibitor design provides evidence for the catalytic versatility of the proteasome","volume":"13","author":"Groll","year":"","journal-title":"Chem. Biol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.1021\/ja058320b","article-title":"Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of \u03b2-Lactone ring opening and a mechanism for irreversible binding","volume":"128","author":"Groll","year":"","journal-title":"J. Am. Chem. Soc."},{"key":"B72","doi-asserted-by":"publisher","first-page":"14981","DOI":"10.1021\/ja806059t","article-title":"Structural analysis of Spiro \u03b2-Lactone proteasome inhibitors","volume":"130","author":"Groll","year":"","journal-title":"J. Am. Chem. Soc."},{"key":"B73","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nature06782","article-title":"A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism","volume":"452","author":"Groll","year":"","journal-title":"Nature"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/cmdc.201000293","article-title":"20S proteasome inhibition: designing noncovalent Linear peptide mimics of the natural product TMC-95A","volume":"5","author":"Groll","year":"2010","journal-title":"ChemMedChem"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2026.02.012","article-title":"Quinoxaline-based UCHL5 inhibitor as a next-generation proteasome-targeting anticancer agent beyond 20S inhibition","author":"Han","year":"2026","journal-title":"J. Adv. Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.7164\/antibiotics.45.1746","article-title":"Epoxomicin, a new antitumor agent of microbial origin","volume":"45","author":"Hanada","year":"1992","journal-title":"J. Antibiot."},{"key":"B77","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1158\/1078-0432.Ccr-15-2616","article-title":"Phase I clinical trial of Marizomib (NPI-0052) in patients with advanced malignancies including multiple myeloma: study NPI-0052-102 final results","volume":"22","author":"Harrison","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.chembiol.2008.03.020","article-title":"Proteasome inhibition by fellutamide B induces nerve growth factor synthesis","volume":"15","author":"Hines","year":"2008","journal-title":"Chem. Biol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1039\/d5np00004a","article-title":"Modulators of the ubiquitin\u2013proteasome system from natural products: chemical structures and their potential for drug discovery","volume":"42","author":"Hitora","year":"2025","journal-title":"Nat. Prod. Rep."},{"key":"B80","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/nature07960","article-title":"Targeting the ubiquitin system in cancer therapy","volume":"458","author":"Hoeller","year":"2009","journal-title":"Nature"},{"key":"B81","doi-asserted-by":"publisher","first-page":"10944","DOI":"10.1158\/0008-5472.CAN-06-1710","article-title":"The internalization and degradation of human copper transporter 1 following Cisplatin exposure","volume":"66","author":"Holzer","year":"2006","journal-title":"Cancer Res."},{"key":"B82","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jpha.2022.12.002","article-title":"Celastrol targeting Nedd4 reduces Nrf2-mediated oxidative stress in astrocytes after ischemic stroke","volume":"13","author":"Hong","year":"2023","journal-title":"J. Pharm. Anal."},{"key":"B83","doi-asserted-by":"publisher","first-page":"101908","DOI":"10.1016\/j.progpolymsci.2024.101908","article-title":"The multifaceted role of tannic acid: from its extraction and structure to antibacterial properties and applications","volume":"160","author":"Hosseini","year":"2025","journal-title":"Prog. Polym. Sci."},{"key":"B84","doi-asserted-by":"publisher","first-page":"114129","DOI":"10.1016\/j.jconrel.2025.114129","article-title":"Co-delivery of SN38 and SR717 activates cGAS-STING for near-infrared II image-guided chemoimmunotherapy","volume":"386","author":"Hou","year":"2025","journal-title":"J. Control. Release."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.3390\/biomedicines10071638","article-title":"Emodin ameliorates the efficacy of Carfilzomib in multiple myeloma cells via apoptosis and autophagy","volume":"10","author":"Hsu","year":"2022","journal-title":"BIOMEDICINES"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.2741\/E335","article-title":"Sanggenon C decreases tumor cell viability associated with proteasome inhibition","volume":"3","author":"Huang","year":"2011","journal-title":"Front. Biosci. Elite Ed."},{"key":"B87","doi-asserted-by":"publisher","first-page":"110056","DOI":"10.1016\/j.biopha.2020.110056","article-title":"Activation of GPR120 by TUG891 ameliorated cisplatin-induced acute kidney injury via repressing ER stress and apoptosis","volume":"126","author":"Huang","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"B88","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1038\/bcj.2012.13","article-title":"Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib","volume":"2","author":"Ishii","year":"2012","journal-title":"Blood Cancer J."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1353056","DOI":"10.3389\/fphar.2024.1353056","article-title":"Natural products' antiangiogenic roles in gynecological cancer","volume":"15","author":"Jia","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"e761","DOI":"10.1038\/cddis.2013.285","article-title":"Marchantin M: a novel inhibitor of proteasome induces autophagic cell death in prostate cancer cells","volume":"4","author":"Jiang","year":"2013","journal-title":"Cell Death Dis."},{"key":"B91","doi-asserted-by":"publisher","first-page":"989032","DOI":"10.3389\/fphar.2022.989032","article-title":"Post-marketing safety of immunomodulatory drugs in multiple myeloma: a pharmacovigilance investigation based on the FDA adverse event reporting system","volume":"13","author":"Jiang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3390\/cancers11070990","article-title":"Anti-tumor activity and epigenetic impact of the polyphenol oleacein in multiple myeloma","volume":"11","author":"Juli","year":"2019","journal-title":"CANCERS"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1002\/cbic.200400096","article-title":"Binding mode of TMC-95A analogues to eukaryotic 20S proteasome","volume":"5","author":"Kaiser","year":"","journal-title":"ChemBioChem"},{"key":"B94","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/cbdv.200490008","article-title":"TMC-95A analogues with endocyclic biphenyl ether group as proteasome inhibitors","volume":"1","author":"Kaiser","year":"","journal-title":"Chem. Biodivers."},{"key":"B95","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.biopha.2014.01.002","article-title":"Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells","volume":"68","author":"Karthik","year":"2014","journal-title":"Biomed. Pharmacother."},{"key":"B96","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.bmcl.2018.11.028","article-title":"Tetradehydrohalicyclamine B, a new proteasome inhibitor from the marine sponge Acanthostrongylophora ingens","volume":"29","author":"Kato","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B97","doi-asserted-by":"publisher","first-page":"8121","DOI":"10.1021\/jacs.5b03833","article-title":"Macyranones: structure, biosynthesis, and binding mode of an unprecedented epoxyketone that targets the 20S proteasome","volume":"137","author":"Keller","year":"2015","journal-title":"J. Am. Chem. Soc."},{"key":"B98","doi-asserted-by":"publisher","first-page":"e50547","DOI":"10.1371\/journal.pone.0050547","article-title":"Withaferin A induces proteasome inhibition, endoplasmic reticulum stress, the heat shock response and acquisition of thermotolerance","volume":"7","author":"Khan","year":"2012","journal-title":"PLoS One"},{"key":"B99","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1039\/c3np20126k","article-title":"From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes","volume":"30","author":"Kim","year":"2013","journal-title":"Nat. Prod. Rep."},{"key":"B100","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1016\/S0960-894X(99)00612-5","article-title":"Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency","volume":"9","author":"Kim","year":"1999","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B101","doi-asserted-by":"publisher","first-page":"2100130","DOI":"10.1002\/ardp.202100130","article-title":"Suppression of the TRIF-dependent signaling pathway of TLRs by epoxomicin","volume":"354","author":"Kim","year":"2021","journal-title":"Arch. Pharm."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.3390\/ph16091294","article-title":"Natural products as drug candidates for redox-related human disease","volume":"16","author":"Kim","year":"2023","journal-title":"Pharmaceuticals"},{"key":"B103","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1021\/ja00061a065","article-title":"Palau'amine: a cytotoxic and immunosuppressive hexacyclic bisguanidine antibiotic from the sponge Stylotella agminata","volume":"115","author":"Kinnel","year":"1993","journal-title":"J. Am. Chem. Soc."},{"key":"B104","doi-asserted-by":"publisher","first-page":"105","DOI":"10.7164\/antibiotics.53.105","article-title":"TMC-95A, B, C, and D, novel proteasome inhibitors produced by Apiospora montagnei Sacc. TC 1093. Taxonomy, production, isolation, and biological activities","volume":"53","author":"Koguchi","year":"2000","journal-title":"J. Antibiot."},{"key":"B105","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s00280-016-2997-7","article-title":"A phase II, open-label trial of bortezomib (VELCADE\u00ae) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer","volume":"77","author":"Kontopodis","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1021\/np300231f","article-title":"Palau'amine and related oroidin alkaloids Dibromophakellin and Dibromophakellstatin inhibit the human 20S proteasome","volume":"75","author":"Lansdell","year":"2012","journal-title":"J. Nat. Prod."},{"key":"B107","doi-asserted-by":"publisher","first-page":"e70038","DOI":"10.1002\/jha2.70038","article-title":"Balancing the risk of cardiotoxicity outcomes in treatment selection for multiple myeloma: a retrospective multicenter evaluation of Ixazomib, lenalidomide, and dexamethasone (IRd) versus Carfilzomib, lenalidomide, and dexamethasone (KRd)","volume":"6","author":"Lee","year":"2025","journal-title":"EJHaem"},{"key":"B108","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1007\/s00277-022-04917-5","article-title":"Anti-CD38 antibody therapy for patients with relapsed\/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes","volume":"101","author":"Leleu","year":"2022","journal-title":"Ann. Hematol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.celrep.2012.11.023","article-title":"Gambogic acid is a tissue-specific proteasome inhibitor in vitro and in vivo","volume":"3","author":"Li","year":"2013","journal-title":"CELL Rep."},{"key":"B110","doi-asserted-by":"publisher","first-page":"e0141681","DOI":"10.1371\/journal.pone.0141681","article-title":"Inhibition on proteasome \u03b21 subunit might contribute to the anti-cancer effects of fangchinoline in human prostate cancer cells","volume":"10","author":"Li","year":"","journal-title":"PLoS One"},{"key":"B111","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1007\/s13277-014-2982-x","article-title":"Investigation the mechanism of the apoptosis induced by lactacystin in gastric cancer cells","volume":"36","author":"Li","year":"","journal-title":"Tumor Biol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nchembio.2326","article-title":"Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11","volume":"13","author":"Li","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3389\/fphar.2018.00334","article-title":"Resveratrol sensitizes Carfilzomib-Induced apoptosis via promoting oxidative stress in multiple myeloma cells","volume":"9","author":"Li","year":"","journal-title":"Front. Pharmacol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.etap.2017.12.004","article-title":"The selectivity of artemisinin-based drugs on human lung normal and cancer cells","volume":"57","author":"Li","year":"","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jconrel.2022.01.015","article-title":"Codelivery of Shikonin and siTGF-\u03b2 for enhanced triple negative breast cancer chemo-immunotherapy","volume":"342","author":"Li","year":"2022","journal-title":"J. Control. Release."},{"key":"B116","doi-asserted-by":"publisher","first-page":"114806","DOI":"10.1016\/j.biopha.2023.114806","article-title":"New advances in the research of clinical treatment and novel anticancer agents in tumor angiogenesis","volume":"163","author":"Li","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1393597","DOI":"10.3389\/fphar.2024.1393597","article-title":"The efficacy and safety of xiao-ban-xia-tang in the treatment of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis","volume":"15","author":"Li","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"114113","DOI":"10.1016\/j.intimp.2025.114113","article-title":"Bortezomib enhances the efficacy of BCMA CAR-T therapy through up-regulating BCMA expression in myeloma cells","volume":"148","author":"Li","year":"","journal-title":"Int. Immunopharmacol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"115293","DOI":"10.1016\/j.intimp.2025.115293","article-title":"Inhibition of PERK pathway promotes TAMs M1 polarization and ER stress in Osteosarcoma cells hindering tumor progression","volume":"163","author":"Li","year":"","journal-title":"Int. Immunopharmacol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.canlet.2015.02.026","article-title":"The role of heat shock proteins in cancer","volume":"360","author":"Lianos","year":"2015","journal-title":"Cancer Lett."},{"key":"B121","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/1521-3773(20020201)41:3<512::aid-anie512>3.0.co;2-r","article-title":"The total synthesis of proteasome inhibitors TMC-95A and TMC-95B: discovery of a new method to generate cis-Propenyl amides","volume":"41","author":"Lin","year":"2002","journal-title":"Angew. Chem.-Int. Ed."},{"key":"B122","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.abb.2010.06.009","article-title":"Fellutamide B is a potent inhibitor of the Mycobacterium tuberculosis proteasome","volume":"501","author":"Lin","year":"2010","journal-title":"Arch. Biochem. Biophys."},{"key":"B123","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1016\/j.apsb.2020.10.009","article-title":"GSH-responsive SN38 dimer-loaded shape-transformable nanoparticles with iRGD for enhancing chemo-photodynamic therapy","volume":"10","author":"Lin","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"B124","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.toxlet.2013.11.021","article-title":"The combination of proteasome inhibitors bortezomib and gambogic acid triggers synergistic cytotoxicity in vitro but not in vivo","volume":"224","author":"Liu","year":"2014","journal-title":"Toxicol. Lett."},{"key":"B125","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.xphs.2022.04.014","article-title":"Co-Delivery of Daunorubicin and homoharringtonine in Folic acid modified-liposomes for enhancing therapeutic effect on Acute Myeloid leukemia","volume":"112","author":"Liu","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1428406","DOI":"10.3389\/fphar.2024.1428406","article-title":"Leonurine: a comprehensive review of pharmacokinetics, pharmacodynamics, and toxicology","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"116855","DOI":"10.1016\/j.bcp.2025.116855","article-title":"The mitochondrial protease ClpP is a promising target for multiple myeloma treatment","volume":"236","author":"Liu","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1124\/jpet.108.138131","article-title":"Point mutation of the proteasome \u03b25 subunit gene is an important mechanism of bortezomib resistance in Bortezomib-Selected variants of Jurkat T cell lymphoblastic Lymphoma\/Leukemia line","volume":"326","author":"L\u00fc","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B129","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ejphar.2011.02.043","article-title":"Shikonin extracted from medicinal Chinese herbs exerts anti-inflammatory effect via proteasome inhibition","volume":"658","author":"Lu","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"110075","DOI":"10.1016\/j.intimp.2023.110075","article-title":"Ubiquitin-specific proteases: vital regulatory molecules in bone and bone-related diseases","volume":"118","author":"Luo","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2174\/1871520614666141114202606","article-title":"Marizomib, a potent second generation proteasome inhibitor from natural origin","volume":"15","author":"Ma","year":"2015","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"B132","doi-asserted-by":"publisher","first-page":"e00286-25","DOI":"10.1128\/aac.00286-25","article-title":"Exploring the in vitro and in vivo antileishmanial potential of Marizomib against Leishmania amazonensis and Leishmania infantum","volume":"69","author":"Machado Patr\u00edcia De","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"B133","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"18953","DOI":"10.1038\/srep18953","article-title":"Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo","volume":"6","author":"Manton","year":"2016","journal-title":"Sci. Rep."},{"key":"B135","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1182\/blood-2010-04-278507","article-title":"Proteasome and HDAC: who's zooming who?","volume":"116","author":"Mcconkey","year":"2010","journal-title":"Blood"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1097\/00001756-200208070-00018","article-title":"Proteasome inhibition causes nigral degeneration with inclusion bodies in rats","volume":"13","author":"Mcnaught","year":"2002","journal-title":"Neuroreport"},{"key":"B137","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/ana.20186","article-title":"Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease","volume":"56","author":"Mcnaught","year":"2004","journal-title":"Ann. Neurol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"10403","DOI":"10.1073\/pnas.96.18.10403","article-title":"Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity","volume":"96","author":"Meng","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B139","doi-asserted-by":"publisher","first-page":"107263","DOI":"10.1016\/j.phrs.2024.107263","article-title":"Histone methyltransferase MLL4 protects against pressure overload-induced heart failure via a THBS4-mediated protection in ER stress","volume":"205","author":"Meng","year":"2024","journal-title":"Pharmacol. Res."},{"key":"B140","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1182\/blood-2006-03-013128","article-title":"NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leuke mia cells","volume":"110","author":"Miller","year":"2007","journal-title":"Blood"},{"key":"B141","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.cbi.2011.08.005","article-title":"Specific and prolonged proteasome inhibition dictates apoptosis induction by marizomib and its analogs","volume":"194","author":"Miller","year":"2011","journal-title":"Chem.-Biol. Interact."},{"key":"B142","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1158\/1535-7163.551.3.5","article-title":"Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity","volume":"3","author":"Mimnaugh","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"B143","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/blood-2005-03-1158","article-title":"Antimyeloma activity of heat shock protein-90 inhibition","volume":"107","author":"Mitsiades","year":"2006","journal-title":"Blood"},{"key":"B144","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.cbpa.2008.06.033","article-title":"Advances in and applications of proteasome inhibitors","volume":"12","author":"Moore","year":"2008","journal-title":"Curr. Opin. Chem. Biol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.3892\/ijo.2013.1870","article-title":"Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells","volume":"42","author":"Moriya","year":"2013","journal-title":"Int. J. Oncol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3892\/ijmm.2011.814","article-title":"Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs","volume":"29","author":"Mujtaba","year":"2012","journal-title":"Int. J. Mol. Med."},{"key":"B147","first-page":"1083","article-title":"Tannic acid potently inhibits tumor cell proteasome activity, increases p27 and bax expression, and induces G1 arrest and apoptosis","volume":"10","author":"Nam","year":"2001","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"B148","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.3324\/haematol.2013.092411","article-title":"Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors","volume":"98","author":"Niewerth","year":"2013","journal-title":"Haematologica"},{"key":"B149","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/cbic.201300778","article-title":"Baceridin, a cyclic hexapeptide from an epiphytic bacillus strain, Inh ibits the proteasome","volume":"15","author":"Niggemann","year":"2014","journal-title":"CHEMBIOCHEM"},{"key":"B150","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40265-017-0841-y","article-title":"Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update","volume":"78","author":"Nijhof","year":"2018","journal-title":"Drugs"},{"key":"B151","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1136\/jclinpath-2015-203414","article-title":"Molecular mechanisms in multiple myeloma drug resistance","volume":"69","author":"Nikesitch","year":"2016","journal-title":"J. Clin. Pathol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1016\/j.bmcl.2022.128566","article-title":"Cell-based screening of extracts of natural sources to search for inhibitors of the ubiquitin-proteasome system and identification of proteasome inhibitors from the fungus Remotididymella sp","volume":"59","author":"Nishimura","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B153","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/1471-2407-11-99","article-title":"Resveratrol protects leukemic cells against cytotoxicity induced by proteasome inhibitors via induction of FOXO1 and p27Kip1","volume":"11","author":"Niu","year":"2011","journal-title":"BMC CANCER"},{"key":"B154","doi-asserted-by":"publisher","first-page":"7085","DOI":"10.1158\/1078-0432.Ccr-09-0822","article-title":"A phase 1 dose escalation Study of the safety and pharmacokinetics of the novel proteasome Inhibitor Carfilzomib (PR-171) in patients with hematologic malignancies","volume":"15","author":"O'connor","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"B155","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","article-title":"Molecular basis of bortezomib resistance: proteasome subunit \u03b25 (PSMB5) gene mutation and overexpression of PSMB5 protein","volume":"112","author":"Oerlemans","year":"2008","journal-title":"Blood"},{"key":"B156","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41429-019-0141-8","article-title":"Lactacystin: first-in-class proteasome inhibitor still excelling and an exemplar for future antibiotic research","volume":"72","author":"\u014cmura","year":"2019","journal-title":"J. Antibiot."},{"key":"B157","doi-asserted-by":"publisher","first-page":"113","DOI":"10.7164\/antibiotics.44.113","article-title":"Lactacystin, a novel microbial metabolite, induces neuritogenesis of n euroblastoma cells","volume":"44","author":"Omura","year":"1991","journal-title":"J. Antibiot."},{"key":"B158","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1200\/Jco.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies","volume":"20","author":"Orlowski","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12964-023-01433-5","article-title":"Interplay between proteasome inhibitors and NF-\u03baB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors","volume":"22","author":"Pakjoo","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"B160","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1158\/1078-0432.CCR-09-1937","article-title":"Romidepsin and belinostat synergize the antineoplastic effect of Bortezomib in Mantle cell lymphoma","volume":"16","author":"Paoluzzi","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"B161","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.phymed.2013.05.002","article-title":"Oleuropein and oleacein may restore biological functions of endothelial progenitor cells impaired by angiotensin II via activation of Nrf2\/heme oxygenase-1 pathway","volume":"20","author":"Parzonko","year":"2013","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"B162","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1159\/000334088","article-title":"Hyponatremia is not a rare adverse event in bortezomib-treated patients","volume":"57","author":"Paydas","year":"2012","journal-title":"Chemotherapy"},{"key":"B163","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3389\/fphar.2020.00251","article-title":"(-)-Sativan inhibits tumor development and regulates miR-200c\/PD-L1 in triple negative breast cancer cells","volume":"11","author":"Peng","year":"","journal-title":"Front. Pharmacol."},{"key":"B164","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3389\/fphar.2020.00378","article-title":"Isoliquiritigenin derivative regulates miR-374a\/BAX axis to suppress triple-negative breast cancer tumorigenesis and development","volume":"11","author":"Peng","year":"","journal-title":"Front. Pharmacol."},{"key":"B165","doi-asserted-by":"publisher","first-page":"806869","DOI":"10.3389\/fphar.2022.806869","article-title":"Maackiain modulates miR-374a\/GADD45A axis to inhibit triple-negative breast cancer initiation and progression","volume":"13","author":"Peng","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/cbic.201200007","article-title":"The carmaphycins: new proteasome inhibitors exhibiting an \u03b1,\u03b2-Epoxyketone warhead from a marine cyanobacterium","volume":"13","author":"Pereira","year":"2012","journal-title":"ChemBioChem"},{"key":"B167","doi-asserted-by":"publisher","first-page":"6282","DOI":"10.1158\/0008-5472.CAN-05-0676","article-title":"Proteasome inhibitors trigger NOXA-Mediated apoptosis in Melanoma and myeloma cells","volume":"65","author":"Qin","year":"2005","journal-title":"Cancer Res."},{"key":"B168","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/j.phytochem.2007.04.036","article-title":"Antifungal dibenzofuran bis(bibenzyl)s from the liverwort Asterella angusta","volume":"68","author":"Qu","year":"2007","journal-title":"Phytochemistry"},{"key":"B169","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1021\/acs.molpharmaceut.2c00752","article-title":"N-2-Hydroxypropylmethacrylamide-Polycaprolactone polymeric micelles in Co-delivery of proteasome inhibitor and polyphenol: exploration of synergism or antagonism","volume":"20","author":"Rani","year":"2023","journal-title":"Mol. Pharm."},{"key":"B170","doi-asserted-by":"publisher","first-page":"138809","DOI":"10.1016\/j.ijbiomac.2024.138809","article-title":"Effect of combination of polyphenols, polysaccharide, and sodium selenite on bortezomib anti-cancer action","volume":"289","author":"Rani","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"B171","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1002\/cncr.21740","article-title":"Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma - final time-to-event results from the SUMMIT trial","volume":"106","author":"Richardson","year":"2006","journal-title":"Cancer"},{"key":"B172","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1182\/blood.V114.22.431.431","article-title":"Phase 1 clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and Relapsed\/Refractory Multiple Myeloma (MM)","volume":"114","author":"Richardson","year":"2009","journal-title":"Blood"},{"key":"B173","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1182\/blood-2013-01-481325","article-title":"PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma","volume":"122","author":"Richardson","year":"2013","journal-title":"Blood"},{"key":"B174","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s11418-013-0778-8","article-title":"Variabines A and B: new \u03b2-carboline alkaloids from the marine sponge Luffariella variabilis","volume":"68","author":"Sakai","year":"2014","journal-title":"J. Nat. Med."},{"key":"B175","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2020-142274","article-title":"Efficacy of Ixazomib and Bortezomib with lenalidomide combination regimens for multiple myeloma: a systematic review","volume":"136","author":"Sana","year":"2020","journal-title":"Blood"},{"key":"B176","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1007\/s00221-017-4962-z","article-title":"Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson\u2019s disease in young and adult mouse","volume":"235","author":"Savolainen","year":"2017","journal-title":"Exp. Brain Res."},{"key":"B177","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1146\/annurev.pharmtox.051208.165340","article-title":"Targeting proteins for destruction by the ubiquitin System: implications for human pathobiology","volume":"49","author":"Schwartz","year":"2009","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B178","doi-asserted-by":"publisher","first-page":"6147","DOI":"10.4049\/jimmunol.164.12.6147","article-title":"The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses","volume":"164","author":"Schwarz","year":"2000","journal-title":"J. Immunol."},{"key":"B179","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s10238-025-01713-z","article-title":"Impact of proteostasis workload on sensitivity to proteasome inhibitors in multiple myeloma","volume":"25","author":"Sedlacek","year":"2025","journal-title":"Clin. Exper. Med."},{"key":"B180","doi-asserted-by":"publisher","first-page":"181","DOI":"10.5414\/CP204224","article-title":"Pharmacokinetic and bioequivalence of lenalidomide in multiple myeloma patients","volume":"61","author":"Shen","year":"2023","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B181","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40265-016-0548-5","article-title":"Ixazomib: first global approval","volume":"76","author":"Shirley","year":"2016","journal-title":"Drugs"},{"key":"B182","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1593\/neo.05520","article-title":"Combination of proteasomal inhibitors Lactacystin and MG132 induced synergistic apoptosis in prostate cancer cells","volume":"7","author":"Shirley","year":"2005","journal-title":"Neoplasia"},{"key":"B183","doi-asserted-by":"publisher","first-page":"8621","DOI":"10.1038\/s41467-024-53022-w","article-title":"Structural elucidation of recombinant Trichomonas vaginalis 20S proteasome bound to covalent inhibitors","volume":"15","author":"Silhan","year":"2024","journal-title":"Nat. Commun."},{"key":"B184","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/j.1365-2141.2010.08144.x","article-title":"Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model","volume":"149","author":"Singh","year":"2010","journal-title":"Br. J. Haematol."},{"key":"B185","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1182\/blood.V128.22.3326.3326","article-title":"Pmd-107: Marizomib, pomalidomide and low dose-dexamethasone combination Study in Relapsed\/Refractory multiple Myeloma (NCT02103335): full enrollment results from a Phase-1 multicenter, open label Study","volume":"128","author":"Spencer","year":"2016","journal-title":"Blood"},{"key":"B186","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B187","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.3390\/molecules30061386","article-title":"Structural insights into salinosporamide a mediated inhibition of the human 20S proteasome","volume":"30","author":"S\u00fclzen","year":"2025","journal-title":"Molecules"},{"key":"B188","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.biopha.2016.07.045","article-title":"CSTMP induces apoptosis and mitochondrial dysfunction in human myeloma RPMI8226 cells via CHOP-dependent endoplasmic reticulum stress","volume":"83","author":"Sun","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"B189","doi-asserted-by":"publisher","first-page":"979111","DOI":"10.3389\/fphar.2023.979111","article-title":"Treatment attrition rates and relevant risk factors in multiple myeloma: a real-world study in China","volume":"14","author":"Tang","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B190","doi-asserted-by":"publisher","first-page":"758992","DOI":"10.3389\/fphar.2021.758992","article-title":"Safety and efficacy analysis of selinexor-based treatment in multiple myeloma, a meta-analysis based on prospective clinical trials","volume":"12","author":"Tao","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B191","doi-asserted-by":"publisher","first-page":"117733","DOI":"10.1016\/j.bmc.2024.117733","article-title":"Modulation of proteasome subunit selectivity of syringolins","volume":"106","author":"Tatsumi","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"B192","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/bjc.2011.546","article-title":"Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment","volume":"106","author":"Taylor-Harding","year":"2012","journal-title":"Br. J. Cancer."},{"key":"B193","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1182\/blood-2008-09-179796","article-title":"Identification of a potent natural triterpenoid inhibitor of proteasome chymotrypsin-like activity and NF-\u03baB with antimyeloma activity in vitro and in vivo","volume":"113","author":"Tiedemann","year":"2009","journal-title":"Blood"},{"key":"B194","doi-asserted-by":"publisher","first-page":"6218","DOI":"10.1016\/j.bmc.2015.07.041","article-title":"Substrate-guided optimization of the syringolins yields potent proteasome inhibitors with activity against leukemia cell lines","volume":"23","author":"Totaro","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"B195","doi-asserted-by":"publisher","first-page":"e00489","DOI":"10.1128\/MCB.00489-18","article-title":"Isoginkgetin, a natural biflavonoid proteasome inhibitor, sensitizes cancer cells to apoptosis via disruption of lysosomal homeostasis and impaired protein clearance","volume":"39","author":"Tsalikis","year":"2019","journal-title":"Mol. Cell. Biol."},{"key":"B196","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.bcp.2008.05.031","article-title":"Physalin B, a novel inhibitor of the ubiquitin-proteasome pathway, triggers NOXA-associated apoptosis","volume":"76","author":"Vandenberghe","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"B197","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ja.2011.35","article-title":"Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma","volume":"64","author":"Vandermolen","year":"2011","journal-title":"J. Antibiot."},{"key":"B198","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3892\/ijo.2014.2804","article-title":"Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells","volume":"46","author":"Wada","year":"2015","journal-title":"Int. J. Oncol."},{"key":"B199","doi-asserted-by":"publisher","first-page":"850","DOI":"10.3923\/ijp.2022.850.855","article-title":"NF-\u03baB signaling pathway and efficacy of Bortezomib-Based combination chemotherapy in patients with non-hodgkin's lymphoma","volume":"18","author":"Wang","year":"2022","journal-title":"Int. J. Pharmacol."},{"key":"B200","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1158\/1078-0432.Ccr-07-5150","article-title":"Proteasome \u03b2 subunit pharmacogenomics: gene resequencing and functional genomics","volume":"14","author":"Wang","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"B201","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1124\/mol.115.100149","article-title":"Structural insights into the pharmacophore of Vinca Domain inhibitors of microtubules","volume":"89","author":"Wang","year":"2016","journal-title":"Mol. Pharmacol."},{"key":"B202","doi-asserted-by":"publisher","first-page":"104678","DOI":"10.1016\/j.fitote.2020.104678","article-title":"Polyprenylated acylphloroglucinols as deubiquitinating protease USP7 inhibitors from Hypericum hookerianum","volume":"146","author":"Wang","year":"","journal-title":"Fitoterapia"},{"key":"B203","doi-asserted-by":"publisher","first-page":"104829","DOI":"10.1016\/j.phrs.2020.104829","article-title":"Novel use for old drugs: the emerging role of artemisinin and its derivatives in fibrosis","volume":"157","author":"Wang","year":"","journal-title":"Pharmacol. Res."},{"key":"B204","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13020-021-00426-1","article-title":"Shikonin promotes ubiquitination and degradation of cIAP1\/2-mediated apoptosis and necrosis in triple negative breast cancer cells","volume":"16","author":"Wang","year":"","journal-title":"Chin. Med."},{"key":"B205","doi-asserted-by":"publisher","first-page":"801328","DOI":"10.3389\/fphar.2021.801328","article-title":"USP14: structure, function, and target inhibition","volume":"12","author":"Wang","year":"","journal-title":"Front. Pharmacol."},{"key":"B206","doi-asserted-by":"publisher","first-page":"114538","DOI":"10.1016\/j.bcp.2021.114538","article-title":"Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway","volume":"188","author":"Wang","year":"","journal-title":"Biochem. Pharmacol."},{"key":"B207","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1182\/blood.2020009856","article-title":"RAR\u03b3 activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway","volume":"139","author":"Wang","year":"2022","journal-title":"Blood"},{"key":"B208","doi-asserted-by":"publisher","first-page":"155156","DOI":"10.1016\/j.phymed.2023.155156","article-title":"Targeting HSP70 chaperones by rhein sensitizes liver cancer to artemisinin derivatives","volume":"122","author":"Wang","year":"2024","journal-title":"Phytomedicine"},{"key":"B209","doi-asserted-by":"publisher","first-page":"10781552251336172","DOI":"10.1177\/10781552251336172","article-title":"Safety, effectiveness and pharmacokinetics of high-dose propylene glycol-free melphalan (EVOMELA) with a prolonged infusion as myeloablative conditioning in Chinese multiple myeloma patients undergoing autologous stem cell transplantation: a prospective phase iv study","author":"Wang","year":"","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B210","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3390\/biomedicines13020351","article-title":"COMMD3 regulates copper metabolism via the ATOX1-ATP7A-LOX axis to promote multiple myeloma progression","volume":"13","author":"Wang","year":"","journal-title":"Biomedicines"},{"key":"B211","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1094\/MPMI.1998.11.8.727","article-title":"Syringolin, a novel peptide elicitor from Pseudomonas syringae pv. syringae that induces resistance to Pyricularia oryzae in rice","volume":"11","author":"W\u00e4spi","year":"1998","journal-title":"Mol. Plant-Microbe Interact."},{"key":"B212","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0944-5013(99)80040-8","article-title":"Identification and structure of a family of syringolin variants: unusual cyclic peptides from Pseudomonas syringae pv. syringae that elicit defense responses in rice","volume":"154","author":"W\u00e4spi","year":"1999","journal-title":"Microbiol. Res."},{"key":"B213","doi-asserted-by":"publisher","first-page":"1496661","DOI":"10.3389\/fphar.2024.1496661","article-title":"Advances of curcumin in nervous system diseases: the effect of regulating oxidative stress and clinical studies","volume":"15","author":"Wei","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B214","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.2174\/1381612826666201118111151","article-title":"Natural products: a rich source of antiviral drug lead candidates for the management of COVID-19","volume":"27","author":"Wijayasinghe","year":"2021","journal-title":"Curr. Pharm. Des."},{"key":"B215","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1021\/acsmedchemlett.5b00401","article-title":"Synthesis and evaluation of macrocyclic peptide aldehydes as potent and selective inhibitors of the 20S proteasome","volume":"7","author":"Wilson","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"B216","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1016\/j.clinthera.2020.08.015","article-title":"Cost-effectiveness of capecitabine plus Irinotecan versus leucovorin plus fluorouracil plus Irinotecan in the second-line treatment of metastatic colorectal cancer in China","volume":"42","author":"Wu","year":"2020","journal-title":"Clin. Ther."},{"key":"B217","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1002\/ijc.30792","article-title":"Bortezomib sensitizes human osteosarcoma cells to adriamycin-induced apoptosis through ROS-dependent activation of p-eIF2\u03b1\/ATF4\/CHOP axis","volume":"141","author":"Xian","year":"2017","journal-title":"Int. J. Cancer."},{"key":"B218","doi-asserted-by":"publisher","first-page":"5767","DOI":"10.1038\/s41467-024-50073-x","article-title":"Leukocyte immunoglobulin-like receptor B1 (LILRB1) protects human multiple myeloma cells from ferroptosis by maintaining cholesterol homeostasis","volume":"15","author":"Xian","year":"2024","journal-title":"Nat. Commun."},{"key":"B219","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.apsb.2019.10.003","article-title":"Targeting autophagy-related protein kinases for potential therapeutic purpose","volume":"10","author":"Xiang","year":"","journal-title":"Acta Pharm. Sin. B"},{"key":"B220","doi-asserted-by":"publisher","first-page":"544754","DOI":"10.3389\/fphar.2020.544754","article-title":"Efficacy and safety of CAR-Modified T cell therapy in patients with relapsed or refractory multiple myeloma: a meta-analysis of prospective clinical trials","volume":"11","author":"Xiang","year":"","journal-title":"Front. Pharmacol."},{"key":"B221","doi-asserted-by":"publisher","first-page":"103947","DOI":"10.1016\/j.jddst.2022.103947","article-title":"Liposomal co-delivery system encapsulating celastrol and paclitaxel displays highly enhanced efficiency and low toxicity against pancreatic cancer","volume":"78","author":"Xiao","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"B222","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.2147\/DDDT.S422512","article-title":"Withaferin A: a dietary supplement with promising potential as an anti-tumor therapeutic for cancer Treatment- pharmacology and mechanisms","volume":"17","author":"Xing","year":"2023","journal-title":"Drug Des. Dev. Ther."},{"key":"B223","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1472-8206.2004.00219.x","article-title":"Effect of ajoene, a natural antitumor small molecule, on human 20S pro teasome activity in vitro and in human leukemic HL60 cells","volume":"18","author":"Xu","year":"2004","journal-title":"Fundam. Clin. Pharmacol."},{"key":"B224","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3892\/mmr.2014.2683","article-title":"Proteasome inhibitor lactacystin enhances cisplatin cytotoxicity by increasing endoplasmic reticulum stress-associated apoptosis in HeLa cells","volume":"11","author":"Xu","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"B225","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.21037\/tcr.2019.09.57","article-title":"Withaferin A suppresses skin tumor promotion by inhibiting proteasome-dependent isocitrate dehydrogenase 1 degradation","volume":"8","author":"Xu","year":"2019","journal-title":"Transl. Cancer Res."},{"key":"B226","doi-asserted-by":"publisher","first-page":"106692","DOI":"10.1016\/j.phrs.2023.106692","article-title":"Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models","volume":"189","author":"Xu","year":"2023","journal-title":"Pharmacol. Res."},{"key":"B227","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/cbic.200300560","article-title":"Simplified synthetic TMC-95A\/B analogues retain the potency of proteasome inhibitory activity","volume":"4","author":"Yang","year":"2003","journal-title":"ChemBioChem"},{"key":"B228","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1158\/0008-5472.Can-05-4529","article-title":"Celastrol, a triterpene extracted from the Chinese Thunder of God Vine, is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice","volume":"66","author":"Yang","year":"2006","journal-title":"Cancer Res."},{"key":"B229","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1124\/mol.106.030015","article-title":"The tumor proteasome is a primary target for the natural anticancer co mpound withaferin a isolated from Indian Winter Cherry","volume":"71","author":"Yang","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"B230","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/jcb.21399","article-title":"Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells","volume":"103","author":"Yang","year":"2008","journal-title":"J. Cell. Biochem."},{"key":"B231","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1002\/ijc.24195","article-title":"Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo","volume":"124","author":"Yang","year":"2009","journal-title":"Int. J. Cancer."},{"key":"B232","doi-asserted-by":"publisher","first-page":"e41214","DOI":"10.1371\/journal.pone.0041214","article-title":"Withaferin A inhibits the proteasome activity in Mesothelioma in vitro and in vivo","volume":"7","author":"Yang","year":"2012","journal-title":"PLOS ONE"},{"key":"B233","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1182\/blood.V128.22.4473.4473","article-title":"Anti-Myeloma activity of a syringolin analog: a dual 20S proteasome inhibitor of beta 2 and 5 subunits","volume":"128","author":"Yoshida","year":"2016","journal-title":"Blood"},{"key":"B234","doi-asserted-by":"publisher","first-page":"101331","DOI":"10.1016\/j.drup.2025.101331","article-title":"Glucocorticoid receptor activated by dexamethasone promotes the chemoresistance and stemness of lung cancer","volume":"85","author":"Yu","year":"2026","journal-title":"Drug resist. Update"},{"key":"B235","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.biopha.2017.10.041","article-title":"New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer","volume":"96","author":"Zhang","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"B236","doi-asserted-by":"publisher","first-page":"808460","DOI":"10.3389\/fphar.2022.808460","article-title":"Anti-Inflammatory efficacy of curcumin as an adjunct to non-surgical periodontal treatment: a systematic review and meta-analysis","volume":"13","author":"Zhang","year":"","journal-title":"Front. Pharmacol."},{"key":"B237","doi-asserted-by":"publisher","first-page":"108639","DOI":"10.1016\/j.intimp.2022.108639","article-title":"Targeted inhibition of the immunoproteasome blocks endothelial MHC class II antigen presentation to CD4+ T cells in chronic liver injury","volume":"107","author":"Zhang","year":"","journal-title":"Int. Immunopharmacol."},{"key":"B238","doi-asserted-by":"publisher","first-page":"974573","DOI":"10.3389\/fonc.2022.974573","article-title":"Combined treatment of marizomib and cisplatin modulates cervical cancer growth and invasion and enhances antitumor potential in vitro and in vivo","volume":"12","author":"Zhang","year":"","journal-title":"Front. Oncol."},{"key":"B239","doi-asserted-by":"publisher","first-page":"109592","DOI":"10.1016\/j.intimp.2022.109592","article-title":"A systematic review on performance analysis of critical time points in multiple myeloma treated by CAR-T cell immunotherapy","volume":"114","author":"Zhang","year":"","journal-title":"Int. Immunopharmacol."},{"key":"B240","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1021\/acs.jnatprod.2c01150","article-title":"Palladium-Catalyzed synthesis, acetylcholinesterase inhibition, and neuroprotective activities of N-Aryl galantamine analogues","volume":"86","author":"Zhang","year":"","journal-title":"J. Nat. Prod."},{"key":"B241","doi-asserted-by":"publisher","first-page":"155710","DOI":"10.1016\/j.phymed.2024.155710","article-title":"Natural products act as game-changer potentially in treatment and management of sepsis-mediated inflammation: a clinical perspective","volume":"130","author":"Zhang","year":"2024","journal-title":"Phytomedicine"},{"key":"B242","doi-asserted-by":"publisher","first-page":"116948","DOI":"10.1016\/j.bcp.2025.116948","article-title":"LncRNA HCG11 regulates selinexor sensitivity in multiple myeloma","volume":"237","author":"Zhang","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"B243","doi-asserted-by":"publisher","first-page":"154986","DOI":"10.1016\/j.phymed.2023.154986","article-title":"Curcumin and analogues against head and neck cancer: from drug delivery to molecular mechanisms","volume":"119","author":"Zhao","year":"2023","journal-title":"Phytomedicine"},{"key":"B244","doi-asserted-by":"publisher","first-page":"436","DOI":"10.12659\/MSM.913889","article-title":"Radix Tetrastigma hemsleyani flavone suppresses cutaneous squamous cell carcinoma A431 cells via proteasome inhibition","volume":"25","author":"Zhong","year":"2019","journal-title":"Med. Sci. Monit."},{"key":"B245","doi-asserted-by":"publisher","first-page":"886198","DOI":"10.3389\/fphar.2022.886198","article-title":"Co-Targeting Tumor angiogenesis and immunosuppressive Tumor microenvironment: a perspective in ethnopharmacology","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B246","doi-asserted-by":"publisher","first-page":"106394","DOI":"10.1016\/j.ijantimicag.2021.106394","article-title":"Artemisinin elevates ergosterol levels of Candida albicans to synergise with amphotericin B against oral candidiasis","volume":"58","author":"Zhu","year":"2021","journal-title":"Int. J. Antimicrob. Agents."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1806787\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:31:56Z","timestamp":1777872716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1806787\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":246,"alternative-id":["10.3389\/fphar.2026.1806787"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1806787","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"article-number":"1806787"}}